MLYS
Price:
$12.49
Market Cap:
$621.09M
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.[Read more]
Industry
Biotechnology
IPO Date
2023-02-10
Stock Exchange
NASDAQ
Ticker
MLYS
According to Mineralys Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 8.55. This represents a change of -44.47% compared to the average of 15.39 of the last 4 quarters.
The mean historical Current Ratio of Mineralys Therapeutics, Inc. over the last ten years is 9.98. The current 8.55 Current Ratio has changed 8.47% with respect to the historical average. Over the past ten years (40 quarters), MLYS's Current Ratio was at its highest in in the June 2023 quarter at 43.42. The Current Ratio was at its lowest in in the March 2022 quarter at 0.
Average
9.98
Median
7.93
Minimum
0.29
Maximum
23.76
Discovering the peaks and valleys of Mineralys Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 663.02%
Maximum Annual Current Ratio = 23.76
Minimum Annual Increase = 0%
Minimum Annual Current Ratio = 0.29
Year | Current Ratio | Change |
---|---|---|
2023 | 23.76 | 74.11% |
2022 | 13.65 | 520.25% |
2021 | 2.20 | 663.02% |
The current Current Ratio of Mineralys Therapeutics, Inc. (MLYS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
13.20
5-year avg
9.98
10-year avg
9.98
Mineralys Therapeutics, Inc.’s Current Ratio is
Company | Current Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mineralys Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Mineralys Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Mineralys Therapeutics, Inc.'s Current Ratio?
How is the Current Ratio calculated for Mineralys Therapeutics, Inc. (MLYS)?
What is the highest Current Ratio for Mineralys Therapeutics, Inc. (MLYS)?
What is the 3-year average Current Ratio for Mineralys Therapeutics, Inc. (MLYS)?
What is the 5-year average Current Ratio for Mineralys Therapeutics, Inc. (MLYS)?
How does the current Current Ratio for Mineralys Therapeutics, Inc. (MLYS) compare to its historical average?